This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.
Best Value Stocks to Buy for February 22nd
by Zacks Equity Research
R, SUN, and HSIC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 22nd, 2022
Best Momentum Stocks to Buy for February 22nd
by Zacks Equity Research
AGCO, HSIC, and MRC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 22, 2022
Abbott (ABT) Gets FDA Approval for CardioMEMS HF System
by Zacks Equity Research
Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.
Medtronic's (MDT) Cryoablation Catheters Get FDA Expanded Nod
by Zacks Equity Research
Medtronic's (MDT) Cardiac Cryoablation is the only ablation catheter approved to treat pediatric AVNRT.
New Strong Buy Stocks for February 22nd
by Zacks Equity Research
AGCO, WIRE, HSIC, MRC, and NTR have been added to the Zacks Rank #1 (Strong Buy) List on February 22, 2022.
Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Integer Holdings (ITGR) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
Quidel (QDEL) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Despite robust revenues from COVID-19 products, Quidel (QDEL) records an overall soft Q4 performance.
Phibro (PAHC) Up 17.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Phibro's (PAHC) stock rallies on continued demand for its products globally and raised 2022 guidance.
Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test
by Zacks Equity Research
Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.
Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.
PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
Zimmer Biomet (ZBH) Business Hurt by China VBP, Price Woe
by Zacks Equity Research
According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
by Zacks Equity Research
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.
LabCorp (LH) Expands Clinical Laboratory Services With New Pact
by Zacks Equity Research
LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.
Henry Schein (HSIC) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 18.89% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for West Pharmaceutical's (WST) Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.
Baxter (BAX) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.
Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel's (QDEL) fourth-quarter results are likely to reflect continued strength across its SARS-related products.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) impressive Breast Imaging and Interventional Breast Solutions business performance.
Zimmer Biomet (ZBH) Opens New ZBEdge Centre in Singapore
by Zacks Equity Research
Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.